S&P 500   4,701.21
DOW   35,754.75
QQQ   399.61
S&P 500   4,701.21
DOW   35,754.75
QQQ   399.61
S&P 500   4,701.21
DOW   35,754.75
QQQ   399.61
S&P 500   4,701.21
DOW   35,754.75
QQQ   399.61

iTeos Therapeutics Stock Forecast, Price & News

+1.71 (+5.18%)
(As of 12/8/2021 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
184,562 shs
Average Volume
300,669 shs
Market Capitalization
$1.23 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive ITOS News and Ratings via Email

Sign-up to receive the latest news and ratings for iTeos Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

iTeos Therapeutics logo

About iTeos Therapeutics

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2a receptor that is an open-label Phase 1/2a clinical trial in adult patients; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2a clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Cambridge, Massachusetts.


iTeos Therapeutics (NASDAQ:ITOS) Shares Gap Up to $32.16
December 7, 2021 |  americanbankingnews.com
iTeos Therapeutics (NASDAQ:ITOS) Stock Price Down 8.1%
December 6, 2021 |  americanbankingnews.com
iTeos Therapeutics (NASDAQ:ITOS) Shares Down 3.8%
November 24, 2021 |  americanbankingnews.com
iTeos Therapeutics (NASDAQ:ITOS) Shares Up 4.4%
November 18, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
Book Value
$10.55 per share


Net Income
$-38.03 million
Pretax Margin




Free Float
Market Cap
$1.23 billion
Not Optionable

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

2.53 out of 5 stars

Medical Sector

103rd out of 1,394 stocks

Biological Products, Except Diagnostic Industry

13th out of 202 stocks

Analyst Opinion: 3.5Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.9 5 -4 -3 -2 -1 -

iTeos Therapeutics (NASDAQ:ITOS) Frequently Asked Questions

Is iTeos Therapeutics a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for iTeos Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" iTeos Therapeutics stock.
View analyst ratings for iTeos Therapeutics
or view top-rated stocks.

Are investors shorting iTeos Therapeutics?

iTeos Therapeutics saw a drop in short interest in the month of November. As of November 15th, there was short interest totaling 636,900 shares, a drop of 21.3% from the October 31st total of 809,500 shares. Based on an average trading volume of 179,900 shares, the days-to-cover ratio is currently 3.5 days. Approximately 2.4% of the company's shares are sold short.
View iTeos Therapeutics' Short Interest

When is iTeos Therapeutics' next earnings date?

iTeos Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, March 23rd 2022.
View our earnings forecast for iTeos Therapeutics

How were iTeos Therapeutics' earnings last quarter?

iTeos Therapeutics, Inc. (NASDAQ:ITOS) released its quarterly earnings results on Wednesday, November, 10th. The company reported $1.86 EPS for the quarter, missing the Zacks' consensus estimate of $4.95 by $3.09. During the same period in the previous year, the business posted ($0.48) earnings per share.
View iTeos Therapeutics' earnings history

What price target have analysts set for ITOS?

4 analysts have issued 12 month target prices for iTeos Therapeutics' shares. Their forecasts range from $37.00 to $54.00. On average, they anticipate iTeos Therapeutics' share price to reach $46.25 in the next year. This suggests a possible upside of 33.1% from the stock's current price.
View analysts' price targets for iTeos Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are iTeos Therapeutics' key executives?

iTeos Therapeutics' management team includes the following people:
  • Dr. Michel Detheux, Pres, CEO & Director (Age 55, Pay $833.75k) (LinkedIn Profile)
  • Mr. Matthew Gall, Chief Financial Officer (Age 44, Pay $628.45k) (LinkedIn Profile)
  • Dr. Joanne Jenkins Lager M.D., Chief Medical Officer (Age 50, Pay $705.56k)
  • Mr. Matthew A. Call M.B.A., Chief Operating Officer (Age 48)
  • Mr. Ryan Baker, Head of Investor Relations
  • Mr. Philippe Brantegem, Vice-Pres of HR

What other stocks do shareholders of iTeos Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other iTeos Therapeutics investors own include Advanced Micro Devices (AMD), GW Pharmaceuticals (GWPH), Trevena (TRVN), Ampio Pharmaceuticals (AMPE), Blink Charging (BLNK), Chegg (CHGG), Centene (CNC), Datadog (DDOG), Global Blood Therapeutics (GBT) and Genocea Biosciences (GNCA).

When did iTeos Therapeutics IPO?

(ITOS) raised $151 million in an initial public offering on Friday, July 24th 2020. The company issued 8,900,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, SVB Leerink and Piper Sandler acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is iTeos Therapeutics' stock symbol?

iTeos Therapeutics trades on the NASDAQ under the ticker symbol "ITOS."

Who are iTeos Therapeutics' major shareholders?

iTeos Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include MPM Asset Management LLC (9.35%), RTW Investments LP (6.68%), BioImpact Capital LLC (5.98%), BlackRock Inc. (4.43%), Alliancebernstein L.P. (3.79%) and EcoR1 Capital LLC (3.69%). Company insiders that own iTeos Therapeutics stock include Ansbert Gadicke, Bioventures 2014 LP Mpm, Bioventures 2018 LP Mpm, Joanne Jenkins Lager, Les B Korsh, Matthew Gall, Michel Detheux and Yvonne Mcgrath.
View institutional ownership trends for iTeos Therapeutics

Which major investors are selling iTeos Therapeutics stock?

ITOS stock was sold by a variety of institutional investors in the last quarter, including MPM Asset Management LLC, BioImpact Capital LLC, Marshall Wace LLP, Healthcare of Ontario Pension Plan Trust Fund, Alliancebernstein L.P., Citigroup Inc., Citadel Advisors LLC, and California State Teachers Retirement System. Company insiders that have sold iTeos Therapeutics company stock in the last year include Ansbert Gadicke, Bioventures 2014 LP Mpm, Bioventures 2018 LP Mpm, Joanne Jenkins Lager, Les B Korsh, Michel Detheux, and Yvonne Mcgrath.
View insider buying and selling activity for iTeos Therapeutics
or view top insider-selling stocks.

Which major investors are buying iTeos Therapeutics stock?

ITOS stock was acquired by a variety of institutional investors in the last quarter, including Rubric Capital Management LP, Tang Capital Management LLC, RTW Investments LP, EcoR1 Capital LLC, Sectoral Asset Management Inc, 683 Capital Management LLC, Two Sigma Advisers LP, and Two Sigma Investments LP.
View insider buying and selling activity for iTeos Therapeutics
or or view top insider-buying stocks.

How do I buy shares of iTeos Therapeutics?

Shares of ITOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is iTeos Therapeutics' stock price today?

One share of ITOS stock can currently be purchased for approximately $34.74.

How much money does iTeos Therapeutics make?

iTeos Therapeutics has a market capitalization of $1.23 billion. The company earns $-38.03 million in net income (profit) each year or $0.29 on an earnings per share basis.

How many employees does iTeos Therapeutics have?

iTeos Therapeutics employs 62 workers across the globe.

What is iTeos Therapeutics' official website?

The official website for iTeos Therapeutics is www.iteostherapeutics.com.

How can I contact iTeos Therapeutics?

The company can be reached via email at [email protected].

This page was last updated on 12/9/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.